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Summary
 
Studying apoptosis induced by T cell receptor (TCR) cross-linking in the T cell hybridoma,
3DO, we found both neutral sphingomyelinase activation and production of ceramide upon
receptor engagement. Pharmacological inhibition of ceramide production by the fungal toxin,
fumonisin B1, impaired TCR-induced interleukin (IL)-2 production and programmed cell
death. Addition of either exogenous ceramide or bacterial sphingomyelinase reconstituted both
responses. Moreover, specific inactivation of neutral sphingomyelinase by antisense RNA in-
hibited IL-2 production and mitogen-activated protein kinase activation after TCR triggering.
These results suggest that ceramide production by activation of neutral sphingomyelinase is an
essential component of the TCR signaling machinery.
Key words: neutral sphingomyelinase • ceramide • T cell receptor • signaling • activation • 
apoptosis
 
T
 
cells recognize peptide fragments in the context of
MHC molecules using the surface TCR complex. The
TCR consists of two distinct groups of transmembrane pro-
teins: a clonally unique and antigen-specific heterodimer and
an associated set of invariant subunits, termed CD3, that are
essential for TCR signal transduction (1). After stimulation
of the TCR, the CD3 complex recruits cytoplasmic tyro-
sine kinases of the src (e.g., fyn and/or lck) and the syk (i.e.,
syk and/or ZAP-70) families. These interactions result in
increased protein tyrosine phosphorylation and trigger nu-
merous biochemical changes, such as elevation of cytosolic
calcium, and protein kinase C (PKC)
 
1
 
 and mitogen-acti-
vated protein (MAP) kinase activation (2, 3).
Integration of these changes will activate various tran-
scription factors that regulate T cell differentiation as well
as immune responses. Developing thymocytes bearing re-
ceptors with high affinity for self-antigens undergo nega-
 
tive selection (4–9)
 
 
 
that is mediated by apoptosis (10–13).
On the other hand, thymic T cells expressing TCRs that
have low affinity for self-MHC molecules are selected to
 
mature to the single positive stage and migrate to the pe-
ripheral lymphoid tissues (9, 14–16). In the periphery, T cell
stimulation can initiate diverse molecular programs leading
to distinct outcomes (activation, anergy, or death) depend-
ing on the differentiation state of the T lymphocyte (i.e.,
responsiveness to a second signal) and/or the context in
which the antigenic peptide is presented (i.e., availability of
a second signal). Peripheral T cells that have expanded in re-
sponse to a foreign antigen are eliminated if the antigen stim-
ulates a large fraction of T cells and persists for a prolonged
 
time (17–21).
 
 
 
This process, called activation-induced cell
death (AICD), is essential to protect the organism against the
deleterious effects of uncontrolled T cell expansion and the
production of toxic levels of cytokines.
We have recently developed a functional system to iden-
tify cDNAs involved in TCR-induced programmed cell
death (PCD; reference 22). DNA sequence analysis of one
of the cDNAs identified with this system indicated that it
could be involved in sphingolipid synthesis (our unpub-
lished data). This suggested to us that the sphingolipid
pathway might be implicated in the apoptotic process initi-
 
1
 
Abbreviations used in this paper:
 
 aSMase, bSMase, and nSMase, acidic, bac-
terial, and neutral SMase; CM, ceramide; CoA, coenzyme A; CsA, cy-
closporin A; EGFP, enhanced green fluorescent protein; Erk, extracellular
signal regulatory kinase; FB1, fumonisin B1; MAP, mitogen-activated
protein; PCD, programmed cell death; PKC, protein kinase C; PLC,
phospholipase C; SM, sphingomyelin; SMase, sphingomyelinase. 
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ated by TCR triggering. Here we demonstrate that TCR
cross-linking results in activation of neutral sphingomyelinase
(nSMase) and production of ceramide (CM). Blockage of
CM production by either the fungal toxin, fumonisin B1
(FB1), or nSMase antisense RNA impaired TCR-induced
IL-2 production and PCD, suggesting that CM is an essen-
tial second messenger of the TCR.
 
Materials and Methods
 
Cell Lines, Abs, and Reagents.
 
The T cell hybridomas 3DO,
2B4, and the human cell line Jurkat were grown in RPMI 1640,
containing 2 mM glutamine, 25 nM 
 
b
 
-mercaptoethanol, 10 mg/ml
streptomycin, 10 mg/ml gentamicin. Anti-CD3
 
e
 
 was purified on
a protein A–Sepharose column from culture supernatants of the
2C11 hybridoma cell line. FITC-conjugated 2C11, anti–mouse
TCR-
 
b
 
 H57, anti–human TCR HIT3a, anti–mouse Fas Jo2,
and anti–hamster IgG Abs were purchased from PharMingen.
Anti–mouse CD28 37.51 was diluted from ascites fluids (23).
Anti–mouse CD45R B220 Ab conjugated to microbeads was
from Miltenyi Biotech GmbH. Anti–mouse class II mAb, clone
M5/114 (24), was biotinylated. FB1, CM, and bacterial SMase
(bSMase) were purchased from Biomol, and daunorubicin and
cyclosporin A (CsA) were from Sigma.
 
Splenic T Cell Purification.
 
Splenic T cells from Balb/c mice
were isolated by negative depletion of B cells and class II
 
1
 
 cells. B
lymphocytes and macrophages were coated with B220 conju-
gated to microbeads and biotinylated rat M5/114 Abs, followed
by incubation with microbeads conjugated to streptavidin. The
cells were passed through a MACS column in the MACS separa-
tor, and the flow through was recovered. The purity of the T cell
preparation was 85–92% as determined by staining of the recov-
ered cells with FITC-conjugated 2C11 Ab.
 
Culture and Stimulation Conditions.
 
For TCR stimulation, 3DO
and 2B4 cells were seeded on plates coated overnight at 4
 
8
 
C with
1 
 
m
 
g/ml of 2C11 Ab. For Fas stimulation, cells were preincu-
bated for 30 min at room temperature with 1 
 
m
 
g/ml of anti–
mouse Fas Ab Jo2, washed twice with medium, and seeded on
plates coated overnight at 4
 
8
 
C with 5 
 
m
 
g/ml of anti–hamster
IgG. Splenic T cells were stimulated using plates coated over-
night with 1 
 
m
 
g/ml of H57 Ab. For costimulation, the anti–
mouse CD28 37.51 Ab was added in solution at a 1:5,000 dilu-
tion from ascites fluids. Jurkat cells were cultured on plates coated
overnight at 4
 
8
 
C with 5 
 
m
 
g/ml of anti–human TCR Ab HIT3a.
FB1 was added to the cell cultures 30 min before stimulation.
Daunorubicin was used at 10 
 
m
 
M. In the experiments shown in
Fig. 4, exogenous CM (10 
 
m
 
M), nSMase (0.1 U/ml), and CsA
(100 nM) were added to the cell cultures at the time of TCR
stimulation.
 
Cell Death Determination, IL-2 Measurements, and Northern Blot
Analysis.
 
The percentage of cell death was assessed by measur-
ing the DNA content of isolated nuclei stained with propidium
iodide (25). IL-2 production was determined by ELISA (Gen-
zyme). Expression of FasL and Nur77 mRNAs was quantitated
by Northern blot analysis. Each lane was loaded with 20 
 
m
 
g of
total RNA isolated from cells treated with 2C11 for the indicated
time. The amount of mRNA loaded was normalized by using
cyclophilin expression as an internal control.
 
CM Quantification.
 
CM was quantified by the diacylglycerol
kinase assay. After incubation with the indicated stimuli, cells
were pelleted by centrifugation, washed twice with ice-cold PBS,
and extracted with chloroform/methanol/1 N HCl (100:100:1,
 
vol/vol/vol). The dried samples were resuspended in a 40-
 
m
 
l
reaction mixture containing 5 mM of cardiolipin (Avanti Polar
Lipids), 1 mM diethylenetriaminepentaacetic acid (DTPA; Sigma),
7.5% octyl-
 
b
 
-
 
d
 
-glucopyranoside (Calbiochem), 10 mM imida-
zole. After five cycles of freeze–thaw, the reaction was started by
adding to the lipids suspension 100 
 
m
 
l of reaction buffer (100
mM imidazole-HCl, pH 6.6, 100 mM NaCl, 25 mM MgCl
 
2
 
,
and 2 mM EGTA), 20 
 
m
 
l of 20 mM dithiothreitol, 19 
 
m
 
l cold 10
mM ATP, 10 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP (3,000 Ci/mmol; DuPont-
NEN), and 10 
 
m
 
l 
 
Escherichia coli
 
 diacylglycerol kinase (Calbio-
chem). After 1 h at room temperature, the reaction was stopped
by adding 0.5 ml of CHCl
 
3
 
/CH
 
3
 
OH/1 N HCl (100:100:1) and
85 
 
m
 
l of PBS, pH 7.4. 100 
 
m
 
l of the lower organic phase was
resolved by thin-layer chromatography on silica gel 60 plates
(Whatman) using a solvent system of chloroform/acetone/meth-
anol/acetic acid/water (10:4:3:1) and visualized by autoradiogra-
phy. Incorporated 
 
32
 
P was quantified by scintillation counting.
The level of CM was determined by comparison with a standard
curve generated concomitantly with known amounts of CM
(CM type III; Sigma).
 
CM Synthase Assay.
 
CM synthase activity was determined as
described previously (26). In brief, 75 
 
3
 
 10
 
6
 
 cells were pelleted,
washed once with cold PBS, and resuspended in 300 
 
m
 
l of homog-
enization buffer (25 mM Hepes, pH 7.4, 5 mM EGTA, 50 mM
NaF, and 10 
 
m
 
g/ml each of leupeptin and soybean trypsin inhib-
itor). Cells were homogenized, and the lysates were centrifuged
at 800 
 
g
 
 for 5 min. The postnuclear supernatant was centrifuged
at 250,000 
 
g
 
 for 30 min. The microsomal membrane pellet was
resuspended in 1 ml of homogenization buffer. Microsomal
membrane protein (75 
 
m
 
g) was incubated in 1 ml reaction mix-
ture containing 2 mM MgCl
 
2
 
, 20 mM Hepes (pH 7.4), 20 
 
m
 
M
defatted BSA (Sigma), varying concentrations (0.2–20 
 
m
 
M) of di-
hydrosphingosine (Biomol), 70 
 
m
 
M unlabeled palmitoyl-coen-
zyme A (palmitoyl-CoA; Sigma), and 3.6 
 
m
 
M (0.2 
 
m
 
Ci) [1-
 
14
 
C]
palmitoyl-CoA (55 mCi/mmol; NEN Life Science Products).
The reaction was started by addition of palmitoyl-CoA, incu-
bated at 37
 
8
 
C for 1 h, and then stopped by extraction of lipids
using 2 ml of chloroform/methanol (1:2). Lower phase was
removed, concentrated, and applied to a silica gel 60 thin-layer
chromatography plate. Dihydroceramide was resolved from free
radiolabeled fatty acid using a solvent system of chloroform/
methanol/3.5 N ammonium hydroxide (85:15:1), identified by
iodine vapor staining based on comigration with CM standards,
and quantified by liquid scintillation counting.
 
Assay for Neutral and Acidic SMase.
 
The cells were harvested
and washed three times with ice-cold PBS, 100 
 
m
 
M Na
 
3
 
VO
 
4
 
 at
4
 
8
 
C. Cells were disrupted by five cycles of freezing–thawing (in
methanol/dry ice) in 100 
 
m
 
l of lysis buffer containing 20 mM
Tris-HCl, pH 7.5, 2 mM EDTA, 5 mM EGTA, 1 mM sodium
vanadate, 10 mM 
 
b
 
-glycerol phosphate, 1 mM PMSF, 5 mM
dithiothreitol, 20 
 
m
 
g/ml each of chymostatin, leupeptin, anti-
pain, and pepstatin. The lysate was centrifuged for 10 min at
1,000 
 
g
 
 at 4
 
8
 
C, and the supernatant (post-nuclear homogenate)
was centrifuged for 60 min at 100,000 
 
g
 
 at 4
 
8
 
C. The resulting
pellet (membrane fraction) was resuspended in 50 
 
m
 
l of lysis
buffer. The membrane preparation was incubated for 30 min at
37
 
8
 
C with 
 
14
 
C-SM (1,000,000 dpm, 10 nmol) in a mixed micelle
assay containing 100 mM Tris-HCl, pH 7.5, 5 mM MgCl
 
2
 
, and
0.1% Triton X-100 (final volume 100 
 
m
 
l). The reaction was
stopped by adding 800 
 
m
 
l of CHCl
 
3
 
/CH
 
3
 
COOH (2:1, vol/vol)
and 250 
 
m
 
l of water. The radioactivity was determined by liquid
scintillation counting. To determine the aSMase activity, mem-
branes were prepared from cells using lysis buffer containing 20 mM 
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Tris-HCl, pH 7.5, 2 mM EDTA, 5 mM EGTA, and 1 mM
PMSF. The micelle assay used contained 100 mM sodium ace-
tate, pH 5, and 0.1% Triton X-100.
 
SM Quantification.
 
3DO cells were grown for 48 h in the
presence of 0.5 
 
m
 
Ci/ml (80 Ci/mmol) [
 
3
 
H]choline chloride. Post-
labeling cells were washed with PBS, reseeded at 0.5 
 
3 
 
10
 
6 
 
cells/
ml in RPMI, and rested for 2–4 h. Cells were then subjected to a
variety of treatments. After treatment, cells were harvested and cell
pellets were resuspended in 3 ml of chloroform/methanol (1:2).
Standard Bligh and Dyer extraction was used to recover lipids. Lip-
ids dried under vacuum were resuspended in 50–100 
 
m
 
l of chloro-
form and spotted on thin-layer chromatography plates, and plates
were developed in chloroform/methanol/acetic acid/water (50:30:
8:5). Plates were sprayed with En
 
3
 
Hance and exposed to film for
24–48 h. The labeled SM spots were scraped into scintillation fluid
and counted in a scintillation counter.
 
Human nSMase Cloning and Transfection.
 
Human nSMase cDNA
was pulled out by PCR from a cDNA library derived from hu-
man fetal liver (Invitrogen) and cloned in pcDNA3.1 vector (In-
vitrogen). The library was screened using primers designed from
the human nSMase sequence recently published (27).
Transient transfections in Jurkat T cells were performed by
electroporating 50 
 
m
 
g of the indicated cDNAs together with 1 
 
m
 
g
of En
 
3
 
Hance Green Fluorescent Protein-N1 (EGFP; Clontech).
The efficiency of transfections was monitored by analyzing the
percentage of EGFP
 
1
 
 cells by flow cytometry. EGFP
 
1
 
 cells were
sorted using a Becton Dickinson FACStar™.
 
Immunoprecipitation and Immunoblot.
 
Cells were lysed in a
buffer comprised of 60 mM Tris-HCl, pH 7.8, containing 150
mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, and
phosphatase and protease inhibitors as described previously (28).
Post-nuclear fractions were precleared with protein A–trisacryl
beads (Pierce) and subjected to immunoprecipitation with a mixed
mAb preparation directed against phospholipase C
 
g
 
1 (PLC
 
g
 
1;
Upstate Biotechnology) bound to protein A/G–agarose beads
(Pierce). Proteins were eluted with sample buffer, resolved by
SDS-PAGE under reducing conditions, and transferred to nitrocel-
lulose membranes (Hybond-C super; Amersham Pharmacia Bio-
tech). Protein detection was via an antiphosphotyrosine primary
Ab (4G10; Upstate Biotechnology) with a second Ab (rabbit anti–
mouse IgG; Cappel) followed by 
 
125
 
I–protein A (ICN Biomedi-
cals). Immunoblots were stripped according to the membrane
manufacturer’s instructions and reprobed with other Abs. Immu-
noblots were scanned on a PhosphorImager (Molecular Dynamics)
to produce the images shown, with no manipulation except for the
adjustment of the exposure range. Densitometry was performed
using ImageQuant™ software (Molecular Dynamics).
 
Results
 
FB1 Inhibits TCR-induced FasL Expression, Cell Death, and
IL-2 Production.
 
To test the hypothesis that the sphingo-
lipid pathway might be implicated in the apoptotic process
initiated by TCR triggering, we used an inhibitor of sphingo-
lipid synthesis, FB1 (29). As shown in Fig. 1 A, this com-
pound protected the T cell hybridoma 3DO from TCR-
induced cell death.
Figure 1. FB1 interferes with TCR
signaling. (A) Pretreatment for 30 min of
3DO cells with FB1 inhibits TCR-
induced apoptosis. The inhibitory effect
is dose dependent. Fas-induced cell death
was not affected by this toxin. Apoptosis
was measured 8 h after TCR triggering
and 4 h after Fas stimulation. (B) Induc-
tion of FasL expression, detectable by
Northern blot analysis 4 h after TCR
cross-linking, is blocked by FB1 (100
mM). Nur77 expression, also induced by
TCR stimulation, is unaffected. Cyclo-
philin (Cyc.) mRNA expression was
used as an internal standard control to
allow normalization to the amount of
mRNA loaded. (C) FB1 also reduces an-
tigen receptor–triggered IL-2  produc-
tion in 3DO cells. In the experiments
shown in the lower panel, IL-2 secretion
was measured 6 h after stimulation of
3DO cells with the 2C11 mAb, in the
presence of the indicated concentrations
of FB1. In the experiments shown in the
upper panel, FB1 was used at a 100 mM
concentration. (D) FB1 also reduces IL-2
production induced by stimulation of
both antigen receptor (TCR) and the
costimulatory receptor CD28 in AE.7
T cell clone and freshly isolated
splenic T cell. Data points shown in A,
C, and D represent the mean of three
independent experiments 6 SE. 
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Stimulation of the TCR on a T cell hybridoma induces
FasL upregulation, and the engagement of Fas by FasL acti-
vates PCD (30–32). Considering that activation of the
sphingolipid pathway has been described to occur after Fas
triggering in several cellular systems (33, 34), we also tested
the effect of FB1 on Fas-induced cell death. This toxin did
not affect Fas-triggered apoptosis (Fig. 1 A), indicating that
FB1 interfered with the TCR-induced death pathway up-
stream of Fas. A key event of TCR-induced apoptosis is
upregulation of FasL. Our results raised the possibility that
FB1 inhibited FasL induction after TCR triggering, which
indeed turned out to be the case. FasL mRNA expression,
detectable 4 h after TCR stimulation, was blocked by FB1
(Fig. 1 B). This inhibition was specific for FasL, since ex-
pression of Nur77 mRNA, another gene known to be in-
duced upon receptor triggering (35, 36), was not affected
(Fig. 1 B).
FB1 could either specifically interfere with PCD or com-
promise early events in TCR signaling. To differentiate be-
tween these two possibilities, we measured IL-2 levels in
culture supernatants after TCR triggering. Pretreatment with
FB1 inhibited IL-2 production in 3DO cells (Fig. 1 C), in-
dicating that this compound interfered with signaling events
that are common to the activation and cell death pathways.
To determine if this observation was true for normal T cells,
the clone A.E7 was tested as well as freshly isolated splenic T
lymphocytes (Fig. 1 D). FB1 reduced production of IL-2 af-
ter simultaneous stimulation of either T cell population with
anti-TCR and anti-CD28 Ab (Fig. 1 D).
 
TCR Triggering Induces nSMase Activation, SM Hydrolysis,
and CM Production.
 
Inhibition of IL-2 production and cell
death by FB1, which is known to interfere with the de novo
synthesis of CM by inhibiting CM synthase, suggested that
CM may participate in early events in TCR signaling.
Therefore, we tested whether TCR triggering induced pro-
duction of CM. As shown in Fig. 2 A, intracellular CM con-
centration increased rapidly upon TCR stimulation.
CM is produced by two distinct routes: de novo synthe-
sis and SM hydrolysis by SMases (37). The de novo synthe-
sis of CM via stimulation of CM synthase has been impli-
cated in the apoptotic pathway (38). Since FB1 has been
shown to inhibit this enzyme (38, 29), we first tested
whether CM production upon TCR triggering resulted
from activation of CM synthase. As shown in Fig. 2 B, CM
synthase activity was not increased upon TCR stimulation.
Next, we analyzed whether TCR engagement induced ac-
tivation of SMases, enzymes responsible for CM generation
induced by stimulation of several membrane receptors, in-
cluding nerve growth factor receptor (NGFR), TNFR,
and Fas (39). SMases are known to exist in at least two
Figure 2. TCR stimulation induces nSMase activation, hydrolysis of SM, and increased intracellular levels of CM. (A) TCR triggering induces CM
production. (B) The activity of CM synthase, which is enhanced by daunorubicin (daun.), is not affected by TCR stimulation. (C) TCR engagement
specifically activates nSMase but not aSMase (C, left) and induces hydrolysis of SM (D). Stimulation of Fas activates both SMases (C, right). (E) TCR
cross-linking induces nSMase activation also in splenic T cells from Balb/c mouse (left), murine T cell hybridoma 2B4 (middle), and human T cell clone
Jurkat (right) cells. Stimulation of purified splenic T cells with an anti-CD28 Ab did not affect nSMase activity (left). Data presented are representative of
at least three independent experiments. 
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forms, a Mg
 
2
 
1
 
-dependent membrane-bound form with a
neutral pH optimum (nSMase) and a lysosomal acidic form
(aSMase) (37). Triggering of the TCR resulted in activa-
tion of nSMase (Fig. 2 C). This activation was selective
since the aSMase, which is readily stimulated upon Fas trig-
gering, was not induced by the TCR (Fig. 2 C). The time
course of nSMase activation paralleled CM production as
well as hydrolysis of the nSMase substrate, SM (Fig. 2, A
and D). Thus, the rapid increase in intracellular CM upon
TCR stimulation depends on activation of nSMase.
To determine whether nSMase activation was a general
and specific consequence of TCR engagement, we ana-
lyzed nSMase activity after triggering of the TCR and
CD28 molecules in other T cell types. Purified splenic
mouse T cells (Fig. 2 E, left), mouse T cell hybridoma 2B4
(Fig. 2 E, middle), and human T cell clone Jurkat (Fig. 2 E,
right), all showed activation of nSMase in response to stim-
ulation of the TCR. An isotype-matched Ab specific for
the costimulatory molecule, CD28, did not activate nSMase
or alter the TCR-dependent induction of this enzyme in
purified splenic T cells (Fig. 2 E). Thus, nSMase is specifi-
cally activated by the TCR in all T cell types analyzed.
 
FB1 Blocks TCR-induced nSMase Activation and CM Pro-
duction.
 
Although FB1 is considered to be an inhibitor of
CM synthase (38, 29), our data suggest that the toxin inter-
feres with the TCR-dependent nSMase activation. There-
fore, we measured nSMase activity, and CM and SM levels
after TCR triggering. We found that FB1 inhibits activation
of this enzyme and, consequently, SM hydrolysis and CM
production (Fig. 3, A–C). In contrast, Fas-induced aSMase
activation was not effected by FB1 (data not shown). Thus,
FB1 inhibits TCR-induced CM production by interfering,
either directly or indirectly, with nSMase activation.
 
The Inhibitory Effect of FB1 on TCR-induced IL-2 Produc-
tion and Apoptosis Is Reverted by Exogenous CM.
 
Altogether,
these findings indicate that FB1 impairs TCR signaling by
inhibiting CM production. However, this toxin could also
inhibit other pathways that are essential for the TCR to
cause IL-2 production, FasL upregulation, and, hence, cell
death. To distinguish between these two possibilities, we
used bSMase or a cell-permeable CM analogue to reconsti-
tute intracellular CM levels. Both treatments reversed the
inhibitory effect of FB1 and restored TCR-induced IL-2
production (Fig. 4 A). However, neither compound recon-
stituted IL-2 production when TCR signaling was inhibited
by CsA, an immunosuppressant that blocks dephosphoryla-
tion and nuclear translocation of the transcription factor nu-
clear factor of activated T cells (NFAT)-c1 (40). Further-
more, C2 CM restored TCR-induced PCD only when
signaling was blocked by FB1 and not by CsA (Fig. 4 B).
Inactivation of nSMase by Antisense RNA Blocks TCR-
induced IL-2 Production. To directly test the involvement of
nSMase in TCR signaling, we cloned by PCR the cDNA
coding for the recently identified and cloned human nSMase
Figure 3. FB1 interferes with the TCR-induced
nSMase activation. Preincubation of 3DO cells with FB1
(100 mM) blocks TCR-induced activation of nSMase (A).
As a result, SM hydrolysis (B) and CM production (C) are
also inhibited. Data shown are representative of five inde-
pendent experiments.
Figure 4. Reconstitution of IL-2 production and cell death by exoge-
nous CM or bacterial SMase. 3DO cells were stimulated with plate-
bound anti-CD3 Ab with or without FB1 preincubation. At the time of
TCR stimulation, exogenous CM (10 mM), bSMase (0.1 U/ml), and
CsA (100 nM) were added as indicated. Supernatants were analyzed for
IL-2 production by ELISA 12 h after stimulation (A). In a separate exper-
iment, cells were tested for apoptosis 8 h after stimulation (B). Data points
represent the mean of three independent experiments 6 SE.1586 Role for nSMase-mediated Ceramide Production in TCR Signaling
(27). Northern blot analyses showed that nSMase is ex-
pressed in all human lymphoid tissues and cell lines tested,
including spleen, lymph node, thymus, peripheral blood
lymphocytes, bone marrow, fetal liver, and Jurkat T cells
(data not shown). The nSMase cDNA was then cloned
into the mammalian expression vector pcDNA3.1, in both
sense and antisense orientation. Jurkat T cells were trans-
fected with either sense or antisense constructs together with
a plasmid coding for EGFP. The efficiency of transfection,
determined by measuring the percentage of EGFP1 cells,
was between 60 and 70% (data not shown). Consistent with
our hypothesis, overexpression of nSMase by transfection of
the sense construct resulted in a significant increase in IL-2
production upon antigen receptor triggering (Fig. 5). In
contrast, expression of the antisense construct reduced IL-2
production by z50% compared with mock-transfected
cells (Fig. 6 A, left). To accurately measure the inhibitory
effect of the antisense vector and to determine whether ex-
pression of the nSMase antisense RNA efficiently depleted
the cellular pool of nSMase protein, we isolated transfected
cells by sorting EGFP1 cells. Sorted cells were then assayed
for TCR-induced IL-2 (Fig. 6 A, right) and CM produc-
tion (Fig. 6 B). In this experimental setting, antisense nSMase
almost completely blocked both IL-2 and CM production.
Taken together, these results demonstrate that CM is an
essential second messenger for the TCR to adequately sig-
nal for IL-2 production and PCD.
nSMase Is Required for TCR-induced MAP Kinase Activa-
tion. In an attempt to localize where in the TCR signal-
ing pathway CM production plays its most important role,
we studied the effect of nSMase inhibition on the activa-
tion of known biochemical signals that are induced upon
TCR stimulation. A critical early event in TCR signal
transduction is the induction of protein tyrosine kinase ac-
tivity with ensuing phosphorylation of multiple substrates
(41). However, inhibition of nSMase activity by transient
transfection with an antisense vector had no effect on the
overall level of protein tyrosine phosphorylation or the pat-
tern of phosphorylated proteins (Fig. 7 A, top). To confirm
this finding, we analyzed directly the phosphorylation sta-
tus of PLCg1, one of the targets of tyrosine kinases during
TCR stimulation (42). No detectable inhibition of TCR-
induced PLCg1 tyrosine phosphorylation was observed in
cells transfected with antisense nSMase (Fig. 7 A, bottom
panels). Taken together, these data suggest that CM pro-
duction is not required for the early events leading to the
activation of this pathway.
TCR ligation activates the guanine nucleotide regula-
tory protein, Ras (43). GTP-bound Ras triggers a cascade
of events that culminate in the phosphorylation and conse-
quent activation of the MAP kinases, extracellular signal
regulatory kinase (Erk)1 and Erk2. Inhibition of nSMase
CM synthesis resulted in diminished MAP kinase activation
(Fig. 7 B, top panels), suggesting that this pathway may be
regulated by CM production. Pharmacological activation
of PKC resulting from treatment of T lymphocytes with
the phorbol ester, PMA, activates MAP kinase in a Ras-
dependent manner. This effect of PMA was not affected by
blockade of CM synthesis (Fig. 7 B, bottom panels). To-
gether with the observation that early tyrosine kinase acti-
vation is insensitive to inhibition of nSMase activity, these
data suggest that CM plays a role in MAP kinase activation
upstream of Ras or on a parallel pathway.
Discussion
In this study, we show that ligation of the TCR induces
production of CM, a molecule that acts as a second mes-
senger in TCR signal transduction. This increase in intra-
cellular CM results from specific activation of nSMase and
SM hydrolysis.
Figure 5. Overexpression of nSMase enhances TCR-induced IL-2 se-
cretion. Jurkat T cells transfected with nSMase cloned in sense (sense) and
stimulated with an anti-CD3e Ab produce significantly higher levels of
IL-2 compared with mock-transfected (pcDNA3) or nontransfected (nt)
controls. The data presented in the right panel represent three separate
transfections, and error bars indicate SEM. IL-2 levels were measured 12 h
after transfection.
Figure 6. Overexpression of antisense
nSMase inhibits TCR-induced CM production
and IL-2 secretion. (A) Jurkat T cells, transfected
with antisense nSMase expression plasmid (anti-
sense) or empty vector (pcDNA3), were tested
for IL-2 production before (left; measurements
taken 20 h after TCR stimulation) and after
(right) sorting of EGFP1 cells. Sorted cells were
also assayed for CM production 45 min after
TCR stimulation (B). Data points represent the
mean of three independent experiments 6 SE.1587 Tonnetti et al.
Recently, an important role for molecules of sphingoid
nature in the modulation of cell response to different extra-
cellular signals has been uncovered. CM has been shown to
act as a key molecule in a new signal transduction pathway
(3). This phospholipid has been implicated in signaling
through several membrane receptors, including nerve growth
factor receptor (NGFR), TNFR, and Fas. Exogenous CM
analogues have been shown to regulate processes such as
PCD (33), IL-2 production (44), and FasL expression (45).
Some downstream targets of this molecule have also been
identified. The action of a 97-kD plasma membrane–bound
serine/threonine protein kinase, CM-activated protein ki-
nase (CAPK), is enhanced by elevation of cellular CM. The
CM-activated protein phosphatase (CAPP), which is a
member of the protein phosphatase 2A class of serine/thre-
onine protein phosphates, is also a target of CM. CM may
also stimulate the guanine nucleotide exchange factor, Vav,
a putative activator of Ras-like guanine nucleotide regula-
tory proteins regulating cytoskeletal assembly in hemato-
poietic cells. Finally, PKCz, an atypical PKC that is insensi-
tive to phorbol esters and diacylglycerol, may also be a direct
target for CM (37, 46).
An early critical event in TCR signaling is the phosphor-
ylation of CD3/z–z chains, docking sites for the T cell–
specific tyrosine kinase, ZAP-70. Activation of ZAP-70
kinase, which is regulated via tyrosine phosphorylation, is
essential for many of the early events in TCR signaling. One
of the targets of tyrosine kinases during TCR stimulation is
PLCg1 (42), whose enzymatic activity is enhanced by ty-
rosine phosphorylation (47). PLCg1 catalyzes the forma-
tion of inositol (1,4,5)-trisphosphate and 1,2-diacylglycerol.
These second messengers induce elevation of intracellular
calcium and activation of PKC, respectively. The increase
in calcium ultimately results in nuclear translocation and
activation of the transcription factor, NFAT (40). PKC and
adapter proteins, some of which are also phosphorylated on
tyrosines, participate in the activation of Ras and the
MAP kinase cascade that ultimately controls the activation
of other transcription factors (43, 48). Here, we present
evidence that CM production is required for TCR-induced
MAP kinase activation, and that CM may act independently
or upstream of Ras. However, CM production is not re-
quired for TCR-induced tyrosine kinase activation. In fact,
like other biochemical messengers of the TCR signal, acti-
vation of nSMase requires protein tyrosine kinase activity
(data not shown).
Our data indicate that CM is a second messenger mole-
cule essential for the antigen receptor to signal for both ac-
tivation and cell death. Further investigation into the
downstream targets of CM action and on how this pathway
is integrated with others to give biological outcomes such
as differentiation, activation, anergy, cell death, and effector
function will help to elucidate the physiological role of CM
in TCR signaling.
We thank Drs. K.L. Holmes and S. Barbieri for cell sorting, and R.H. Schwartz and L. Samelson for helpful
discussions and comments on the manuscript.
Figure 7. CM production is required for
MAP kinase activation. (A) Jurkat cells,
transfected with either empty vector (Cont)
or antisense nSMase (as SM), were treated
with medium alone or an anti-TCR Ab
(CD3 3 CD3) for 2 min at 378C and im-
mediately lysed. Total protein tyrosine
phosphorylation was measured by Western
blot (WB) analysis of whole-cell lysates
(WCL) with an antiphosphotyrosine Ab
(anti-pY; top). Three bands, attributable to
LAT, Cbl, and ZAP-70 based on their elec-
trophoretic mobility and the use of Abs
against known tyrosine kinase substrates
(data not shown), are indicated. Tyrosine
phosphorylation of PLCg1 was directly as-
sayed by probing PLCg1 immunoprecipi-
tates (IP) with the antiphosphotyrosine Ab
(middle). Equivalent amounts of PLCg1
were immunoprecipitated in each experi-
mental sample, as shown by stripping and
reprobing the blot with an anti-PLCg1 Ab
(bottom). (B) Transfected cells were stimu-
lated with either an anti-TCR Ab (CD3 3
CD3) for 5 min or PMA for 10 min.
Whole-cell lysates were first probed with an
Ab specific for phosphorylated Erk1 and
Erk2 (anti-pErk). After stripping, mem-
branes were reprobed with an anti-Erk Ab
to verify that equivalent amounts of MAP
kinases were loaded in each lane.1588 Role for nSMase-mediated Ceramide Production in TCR Signaling
Address correspondence to Luciano D’Adamio, T-Cell Apoptosis Unit, Laboratory of Cellular and Molecu-
lar Immunology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892. Phone:
301-496-3842; Fax: 301-402-3184; E-mail: ldadamio@atlas.niaid.nih.gov
Received for publication 20 October 1998 and in revised form 27 January 1999.
References
1. Wilson, I.A., and K.C. Garcia. 1997. T-cell receptor struc-
ture and TCR complexes. Curr. Opin. Struct. Biol. 7:839–848.
2. Wange, R.L., and L.E. Samelson. 1996. Complex complexes:
signaling at the TCR. Immunity. 5:197–205.
3. Berridge, M.J. 1997. Lymphocyte activation in health and
disease. Crit. Rev. Immunol. 17:155–178.
4. Kappler, J.W., N. Roehm, and P. Marrack. 1987. T cell tol-
erance by clonal elimination in the thymus. Cell. 49:273–280.
5. Kappler, J.W., U. Staerz, J. White, and P. Marrack. 1988.
Self-tolerance eliminates T cells specific for Mls-modified
products of the major histocompatibility complex. Nature.
332:35–40.
6. MacDonald, H.R., R. Schneider, R.K. Lees, R.C. Howe,
H. Acha-Orbea, H. Restenstein, R.M. Zinkernagel, and H.
Hengartner. 1988. T-cell receptor Vb use predicts reactivity
and tolerance to Mlsa-encoded antigen. Nature. 332:40–45.
7. Hengartner, H., B. Odermatt, R. Shneider, M. Schreirer, G.
Walle, H.R. MacDonald, and R.M. Zinkernagel. 1988. De-
letion of self-reactive T cells before entry into the thymus
medulla. Nature. 336:388–390.
8. Kisielow, P., H. Bluethmann, U.D. Staerz, M. Steinmetz,
and H. Von Boehmer. 1988. Tolerance in T-cell receptor
transgenic mice involves deletion of nonmature CD4181
thymocytes. Nature. 333:742–746.
9. Sha, W.C., C.A. Nelson, R.D. Newberry, D.M. Kranz, J.H.
Russell, and D.Y. Loh. 1988. Positive and negative selection
of an antigen receptor in transgenic mice. Nature. 336:73–76.
10. Shi, Y., R.P. Bissonnette, N. Parfrey, M. Szalay, R.T. Kubo,
and D.G. Green. 1991. In vivo administration of monoclonal
antibodies to the CD3 T-cell receptor complex induces cell
death (apoptosis) in immature thymocytes. J. Immunol. 146:
3340–3346.
11. Smith, C.A., G.T. Williams, R. Kingston, E.J. Jenkinson,
and J.J.T. Owen. 1989. Antibodies to CD3/T-cell receptor
complex induce death by apoptosis in immature T cells in
thymic cultures. Nature. 337:181–184.
12. Murphy, K.M., A.B. Heimberger, and D.Y. Loh. 1990. In-
duction by antigen of intrathymic apoptosis of CD41 CD81
TCRlo thymocytes in vivo. Science. 250:1720–1723.
13. D’Adamio, L., L.K. Clayton, K.M. Awad, and E.L. Rein-
herz. 1992. Negative selection of thymocytes: a novel PCR-
based molecular analysis detects requirements for macromo-
lecular synthesis. J. Immunol. 149:3550–3553.
14. Berg, L.J., B. Fazekas de St. Groth, A.M. Pullen, and M.M.
Davis. 1989. Phenotypic differences between ab versus b
T-cell receptor transgenic mice undergoing negative selec-
tion. Nature. 340:559–562.
15. Blackman, M.A., J.W. Kappler, and P. Marrack. 1989. Influ-
ence of the MHC on positive selection of Vb17a1 T cells.
Science. 244:214–217.
16. MacDonald, H.R., R.K. Lees, R. Schneider, R.M. Zinker-
nagel, and H. Hengartner. 1988. Positive selection of CD41
thymocytes controlled by MHC class II gene products. Na-
ture. 336:471–473.
17. Webb, S., C. Morris, and J. Sprent. 1990. Extrathymic toler-
ance of mature T cells: clonal elimination as a consequence of
immunity. Cell. 63:1249–1256.
18. Kawabe, Y., and A. Ochi. 1990. Selective anergy of Vb81,
CD41 T cells in Staphylococcus enterotoxin B–primed mice. J.
Exp. Med. 172:1065–1070.
19. Kawabe, Y., and A. Ochi. 1991. Programmed cell death and
extrathymic reduction of Vb81CD41 T cells in mice tolerant
to Staphylococcus aureus enterotoxin B. Nature. 349:245–248.
20. Lenardo, M.J. 1991. Interleukin-2 programs mouse ab T lym-
phocytes for apoptosis. Nature. 353:858–861.
21. D’Adamio, L., K.M. Awad, and E.L. Reinherz. 1993. Thy-
mic and peripheral deletion of antigen-specific T cells might
cooperate in establishing self-tolerance. Eur. J. Immunol. 23:
747–753.
22. Vito, P., E. Lacana, and L. D’Adamio. 1996. Interfering with
apoptosis: Ca21-binding protein ALG-2 and Alzheimer’s dis-
ease gene ALG-3. Science. 271:521–525.
23. Harding, F.A., J.A. McArthur, D.H. Gross, D.H. Raulet, and
J.P. Allison. 1992. CD28-mediated signaling co-stimulates
murine T cells and prevents induction of anergy in T-cell
clones. Nature. 356:607–609.
24. Bhattacharya, A., M.E. Dorf, and T.A. Springer. 1981. A
shared alloantigenic determinant on Ia antigens encoded by
the I-A and I-E subregions: evidence for I region gene dupli-
cation. J. Immunol. 127:2488–2495.
25. Nicoletti, I., G. Migliorati, M.C. Pagliacci, F. Grignani, and
C. Riccardi. 1991. Simple method for measuring thymocytes
apoptosis by propidium iodide staining and flow cytometry.
J. Immunol. Methods. 139:271–279.
26. Liu, J., S. Mathias, Z. Yang, and R.N. Kolesnick. 1994.
Renaturation and TNFa stimulation of 97 kDa ceramide-
activated protein kinase. J. Biol. Chem. 269:3047–3052.
27. Tomiuk, S., K. Hofmann, M. Nix, M. Zumbansen, and W.
Stoffel. 1998. Cloned mammalian neutral sphingomyelinase:
functions in sphingolipid signaling? Proc.  Natl. Acad. Sci.
USA. 95:3638–3643.
28. Stoica, B., K.E. DeBell, L. Graham, B.L. Rellahan, M.A.
Alava, J. Laborda, and E. Bonvini. 1998. The amino-terminal
Src homology 2 domain of phospholipase C gamma 1 is es-
sential for TCR-induced tyrosine phosphorylation of phos-
pholipase C gamma 1. J. Immunol. 3:1059–1066.
29. Harel, R., and A.H. Futerman. 1993. Inhibition of sphingo-
lipid synthesis affects axonal outgrowth in cultured hippo-
campal neurons. J. Biol. Chem. 268:14476–14481.
30. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi,
F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F.
Ware, and D. Green. 1995. Cell-autonomous Fas (CD95)/
Fas-ligand interaction mediates activation-induced apoptosis
in T-cell hybridomas. Nature. 373:385–386.
31. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H.
Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/
(Fas/CD95). Nature. 373:438–441.
32. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib,1589 Tonnetti et al.
D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995.
Fas(CD95)/FasL interactions required for programmed cell
death after T-cell activation. Nature. 373:444–448.
33. Kolesnick, N.R., A. Haimovitz-Friedman, and Z. Fuks.
1994. The sphingomyelin signal transduction pathway medi-
ates apoptosis for tumor necrosis factor, Fas, and ionizing ra-
diation. Biochem. Cell Biol. 72:471–474.
34. Hannun, Y.A. 1996. Function of ceramide in coordinating
cellular response to stress. Science. 274:1855–1859.
35. Woronicz, J.D., B. Calnan, V. Ngo, and A. Winoto. 1994.
Requirement for the orphan steroid receptor Nur77 in apop-
tosis of T-cell hybridomas. Nature. 367:277–281.
36. Zheng-Gang, L., S.L. Smith, K.A. McLaughlin, M.
Schwartz, and B.A. Osborne. 1994. Apoptotic signal deliv-
ered through the T-cell receptor of a T-cell hybrid required
the immediate-early gene nur77. Nature. 367:281–284.
37. Spiegel, S., D. Foster, and R.N. Kolesnick. 1996. Signal
transduction through lipid second messengers. Curr. Opin.
Cell Biol. 8:159–167.
38. Bose, R., M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z.
Fuks, and R.N. Kolesnick. 1995. Ceramide synthase medi-
ates daunorubicin-induced apoptosis: an alternative mecha-
nism for generating death signals. Cell. 82:405–414.
39. Pushkareva, M., L.M. Obeid, and Y.A. Hannun. 1995. Cer-
amide: an endogenous regulator of apoptosis and growth
suppression.  Immunol. Today. 16:294–297.
40. Rao, A., C. Luo, and P.G. Hogan. 1997. Transcription fac-
tors of the NFAT family: regulation and function. Annu.
Rev. Immunol. 15:707–747.
41. Weiss, A. 1993. T cell antigen receptor signal transduction: a
tale of tails and cytoplasmic protein-tyrosine kinases. Cell. 73:
209–212.
42. Park, D.J., H.V. Rho, and S.G. Rhee. 1991. CD3 stimula-
tion causes phosphorylation of phospholipase C gamma 1 on
serine and tyrosine residues in a human T cell line. Proc. Natl.
Acad. Sci. USA. 88:5453–5457.
43. Cantrell, D.A., J.D. Graves, M. Izquierido, S. Lucas, and J.
Downward. 1992. T lymphocyte activation signal. Ciba
Found. Symp. 164:208–218.
44. Mathias, S., A. Younes, C.C. Kan, I. Orlow, C. Joseph, and
R.N. Kolesnick. 1993. Activation of the sphingomyelin sig-
naling pathway in intact EL4 cells and in a cell-free system by
IL-1b. Science. 259:519–521.
45. Herr, I., D. Wilhem, T. Böhler, P. Angel, and K.M. Deba-
tin. 1997. Activation of CD95 (APO-1/Fas) signaling by cer-
amide mediates cancer therapy-induced apoptosis. EMBO
(Eur. Mol. Biol. Organ.) J. 16:6200–6208.
46. Müller, G., M. Ayoub, P. Storz, J. Rennecke, D. Fabbro,
and K. Pfizenmaier. 1995. PKC z is a molecular switch in
signal transduction of TNF-a, bifunctionally regulated by cer-
amide and arachidonic acid. EMBO (Eur. Mol. Biol. Organ.)
J. 14:1961–1969.
47. Nishibe, S., M.I. Wahl, S.M. Hernandez-Sotomayor, N.K.
Tonks, S.G. Rhee, and G. Carpenter. 1990. Increase of the
catalytic activity of phospholipase C-gamma 1 by tyrosine
phosphorylation. Science. 250:1253–1256.
48. Zhao, H., Y.Y. Li, R.V. Fucini, S.E. Ross, J.E. Pessin, and
G.A. Korentzky. 1997. T cell receptor-induced phosphoryla-
tion of Sos requires activity of CD45, Lck, and protein kinase
C, but not ERK. J. Biol. Chem. 272:21625–21634.